Real-world effectiveness of PARP inhibitors after CDK4/6 inhibitor therapy in BRCA-mutated HR-positive/HER2-negative advanced breast cancer.

3 , the impact of line of administration on rwPFS was more pronounced for PARPi than for other post-CDK4/6i treatments: both ET and monoCT showed a relatively stable rwPFS across treatment lines (HR 0.91, 95% CI 0.58–1.43, p = 0.697 and HR 1.15, 95% CI 0.69–1.90, p = 0.593, respectively), while for polyCT, although a decrease in rwPFS was observed with later-line use, the difference did not reach statistical significance (HR 1.85, 95% CI 0.95–3.59, p = 0.069).

also in 111,027 other papers